IONS: Licenses Zilganersen
Ionis Pharmaceuticals licenses zilganersen to Recordati for $30M upfront payment for all countries outside the US
- Recordati brings deep rare disease expertise and proven capabilities in commercialization, access and country-specific regulatory environments - - Ionis to independently commercialize zilganersen in the U.S. assuming FDA approval -